IPP Bureau
Briefs: Lupin and Alembic
By IPP Bureau - March 14, 2023
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
Dr. Lal PathLabs selects Kyndryl for cloud services management
By IPP Bureau - March 14, 2023
Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces
Alpla and Inden pharma form joint venture
By IPP Bureau - March 14, 2023
ALPLA is expanding its presence in the global market for pharmaceutical packaging by establishing a joint venture with Inden Pharma
Precision appoints John Hubbard, PhD, as Board of Directors Chair
By IPP Bureau - March 14, 2023
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
By IPP Bureau - March 13, 2023
The company will be submitting the responses to US FDA observations within stipulated timeline
Zydus receives final approval from the USFDA for Olanzapine
By IPP Bureau - March 13, 2023
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Agilent announces digital pathology workflow solution
By IPP Bureau - March 13, 2023
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
Keytruda + chemotherapy improved overall survival versus chemotherapy alone as for advanced malignant pleural mesothelioma
By IPP Bureau - March 12, 2023
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Marksans Pharma announces USFDA approval for Famotidine Tablets
By IPP Bureau - March 11, 2023
Marksans' OTC Famotidine Tablets USP are acid reducers
USFDA completes inspection of Lupin’s Vizag facility
By IPP Bureau - March 11, 2023
The inspection concluded with no observations
Baxter launches the 'Choose Freedom' campaign for kidney disease patients
By IPP Bureau - March 11, 2023
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Build a sustainable healthcare and lifesciences industry, say Experts
By IPP Bureau - March 11, 2023
Time to combine innovation, access and technology to deliver positive patient outcomes
IIT Kanpur and Reliance Life Sciences join forces to revolutionize gene therapy for hereditary eye diseases
By IPP Bureau - March 11, 2023
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Bachem raises $116 million through capital increase
By IPP Bureau - March 11, 2023
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
NATCO launches additional strengths for generic version of Revlimid in USA
By IPP Bureau - March 10, 2023
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
